The BEV1L study: Do real‐world outcomes associated with the addition of bevacizumab to first‐line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
In the BEV1L study, which used data from a US‐nationwide, electronic health record–derived, deidentified database of patients with epithelial ovarian cancer, the real‐world clinical benefit of adding bevacizumab to first‐line chemotherapy was limited to patients with high‐risk prognostic factors (defined as Stage IV disease or Stage III disease with visible residual disease or no evidence of surgery). These results are consistent with findings from the GOG‐0218 and ICON7 clinical trials.
